Video

Graft Versus Host Disease No Longer Poses High Risk to Transplant Patients

Graft versus host disease (GVHD) used to present such a risk to transplant patients, an estimate 10-15% of patients would develop a fatal case of it.

News

Congressman Kennedy Announces Over $7.7 Million for State-of-the-Art Biobank at Roswell Park

Congressman Kennedy announced $7,731,872 in funding for the Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of the National ...

News

Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies

A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...

News

Next Generation Armored Car T-Cell Therapy Trial Now Open

This Phase I/II trial will test the effectiveness, safety, side effects, and best dose of CD19-targeted Chimeric Antigen Receptor (CAR) modified T cells genetically engineered to secrete interleukin 12 (IL-12) in patients with hematologic B-cell malignancies.

News

Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant

Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Video

First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park

Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.